Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 9/20 | 0.42 |
| ▸ | BTK | Q06187 | 5/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | ITK | Q08881 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30306474 | 0.79 | BRD4 (0.54) | SYKEGFRBRD4JAK2HDAC1 | |
| SCHEMBL265007 | 0.79 | BRD4 (0.54) | SYKEGFRBRD4JAK2HDAC1 | |
| SCHEMBL657579 | 0.78 | SYK (0.72) | SYKEGFRBTKAURKARET | |
| SCHEMBL9945499 | 0.78 | EGFR (0.64) | SYKEGFRITKJAK2HDAC1 | |
| SCHEMBL263864 | 0.78 | MEN1 (0.55) | SYKEGFRJAK3JAK2 | |
| SCHEMBL12518610 | 0.77 | MAPK1 (0.58) | SYKEGFRBTK | |
| SCHEMBL9923767 | 0.77 | SYK (0.51) | SYKEGFRBTKJAK3ITK | |
| SCHEMBL19960624 | 0.77 | SYK (0.51) | SYKEGFRBTKJAK3ITK | |
| SCHEMBL265330 | 0.76 | SYK (0.48) | SYKEGFRBTKJAK3ITK | |
| SCHEMBL13606356 | 0.76 | EGFR (0.61) | SYKEGFRBTKJAK3ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | SYK 610/4885EGFR 460/4885BTK 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.